Abstract | Background: Design and Setting: This retrospective study included 60 male patients with CCPHD on a relatively large case series in a single center from mainland China. Twenty-nine patients who received gonadotropin therapy alone were defined as the Gn group, while 31 patients treated with a combination of rhGH and gonadotropins were defined as GH/Gn group. Results: Spermatogenesis rate was 96.77% (30/31) and 62.07% (18/29) in the GH/Gn and Gn group, respectively (P < 0.001). The time for initial sperm appearance in the GH/Gn group was shorter than in the Gn group (14 versus 23 months, P < 0.001). A higher level of serum testosterone was achieved in the GH/Gn group than in the Gn group (4.79 versus 3.38 ng/mL, P = 0.026). After adjustment for potential confounders, rhGH supplementation was an independent beneficial factor on spermatogenesis (HR = 2.294, 95% CI: 1.143-4.604, P = 0.019). Conclusions: rhGH induces earlier spermatogenesis in patients with CCPHD, which encourages the co-treatment with rhGH and gonadotropins in CCPHD patients.
|
Authors | Yiyi Zhu, Min Nie, Xi Wang, Qibin Huang, Bingqing Yu, Rui Zhang, Junyi Zhang, Bang Sun, Jiangfeng Mao, Xueyan Wu |
Journal | Frontiers in endocrinology
(Front Endocrinol (Lausanne))
Vol. 13
Pg. 868047
( 2022)
ISSN: 1664-2392 [Print] Switzerland |
PMID | 35528001
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 Zhu, Nie, Wang, Huang, Yu, Zhang, Zhang, Sun, Mao and Wu. |
Chemical References |
- Gonadotropins
- Recombinant Proteins
- Human Growth Hormone
- Testosterone
|
Topics |
- Adult
- Gonadotropins
(therapeutic use)
- Human Growth Hormone
(therapeutic use)
- Humans
- Hypopituitarism
(drug therapy)
- Male
- Recombinant Proteins
(therapeutic use)
- Retrospective Studies
- Spermatogenesis
- Testosterone
|